Friday, August 22, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp.

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

Some 1200 patients a year in England are set to benefit from a “breakthrough” life extending treatment for bladder cancer after the National Institute for Health and Care Excellence (NICE) approved it ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.